What is Quest Diagnostics Inc's earnings per share (EPS)?

Quest Diagnostics Inc (DGX) reported diluted earnings per share of $8.75 for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Quest Diagnostics Inc Financials

DGX

FY2025 annual

Revenue $11.0B +11.8% YoY

Net Income $992.0M +13.9% YoY

EPS (Diluted) $8.75 +13.8% YoY

Free Cash Flow $1.4B +49.5% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Quest Diagnostics Inc (DGX) reported $11.0B in revenue for fiscal year 2025, up 11.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DGX FY2025 2026-04-22

Cash-rich operations are carrying an acquisition-heavy balance sheet, with recovery driven more by execution than margin reinvention.

From FY2023 to FY2025, revenue recovered by $1.8B while gross margin stayed near 33%, yet free cash flow climbed from $864M to $1.36B. Because operating cash flow reached $1.89B against net income of $992M, the rebound is showing up in cash conversion, not just accrual earnings.

With $8.95B of goodwill inside $16.23B of assets, this is a deal-built balance sheet more than a hard-asset one. Yet capital spending of $527M against operating cash flow of $1.89B shows the operating engine itself does not need heavy reinvestment to keep producing cash.

Cash ended FY2025 at just $420M and the current ratio was 1.0x, so the company keeps only a narrow liquid buffer. Even so, debt-to-equity improved from 0.8x in FY2024 to 0.7x in FY2025 while buybacks and dividends still totaled $803M, indicating operations, not idle cash, are financing both shareholder returns and balance-sheet repair.

Financial Health Signals

Financial Health Score 55/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Quest Diagnostics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Quest Diagnostics Inc has an operating margin of 14.1%, meaning the company retains $14 of operating profit per $100 of revenue. This strong profitability earns a score of 78/100, reflecting efficient cost management and pricing power. This is up from 13.6% the prior year.

Growth

Quest Diagnostics Inc's revenue grew 11.8% year-over-year to $11.0B, a solid pace of expansion. This earns a growth score of 63/100.

Leverage

Quest Diagnostics Inc has elevated debt relative to equity (D/E of 0.72), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 28/100, reflecting increased financial risk.

Liquidity

Quest Diagnostics Inc's current ratio of 1.04 is below the typical benchmark, resulting in a score of 21/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Quest Diagnostics Inc converts 12.3% of revenue into free cash flow ($1.4B). This strong cash generation earns a score of 69/100.

Returns

Quest Diagnostics Inc earns a strong 13.8% return on equity (ROE), meaning it generates $14 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 70/100. This is up from 12.8% the prior year.

Altman Z-Score Safe

3.63

Quest Diagnostics Inc scores 3.63, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

8/9

Quest Diagnostics Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.90x

For every $1 of reported earnings, Quest Diagnostics Inc generates $1.90 in operating cash flow ($1.9B OCF vs $992.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.62x

Quest Diagnostics Inc earns $5.62 in operating income for every $1 of interest expense ($1.6B vs $277.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$11.0B

YoY+11.8%

5Y CAGR+3.2%

10Y CAGR+3.9%

Quest Diagnostics Inc generated $11.0B in revenue in fiscal year 2025. This represents an increase of 11.8% from the prior year.

EBITDA

$2.1B

YoY+15.6%

5Y CAGR-1.8%

10Y CAGR+2.2%

Quest Diagnostics Inc's EBITDA was $2.1B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.6% from the prior year.

Net Income

$992.0M

YoY+13.9%

5Y CAGR-7.1%

10Y CAGR+3.4%

Quest Diagnostics Inc reported $992.0M in net income in fiscal year 2025. This represents an increase of 13.9% from the prior year.

EPS (Diluted)

$8.75

YoY+13.8%

5Y CAGR-3.5%

10Y CAGR+6.0%

Quest Diagnostics Inc earned $8.75 per diluted share (EPS) in fiscal year 2025. This represents an increase of 13.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.4B

YoY+49.5%

5Y CAGR-3.1%

10Y CAGR+9.3%

Quest Diagnostics Inc generated $1.4B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 49.5% from the prior year.

Cash & Debt

$420.0M

YoY-23.5%

5Y CAGR-18.4%

10Y CAGR+12.2%

Quest Diagnostics Inc held $420.0M in cash against $5.2B in long-term debt as of fiscal year 2025.

Shares Outstanding

110M

YoY-1.0%

5Y CAGR-3.8%

10Y CAGR-2.6%

Quest Diagnostics Inc had 110M shares outstanding in fiscal year 2025. This represents a decrease of 1.0% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

33.2%

YoY+0.4pp

5Y CAGR-5.3pp

10Y CAGR-4.6pp

Quest Diagnostics Inc's gross margin was 33.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Operating Margin

14.1%

YoY+0.5pp

5Y CAGR-6.8pp

10Y CAGR-4.6pp

Quest Diagnostics Inc's operating margin was 14.1% in fiscal year 2025, reflecting core business profitability. This is up 0.5 percentage points from the prior year.

Net Margin

9.0%

YoY+0.2pp

5Y CAGR-6.2pp

10Y CAGR-0.5pp

Quest Diagnostics Inc's net profit margin was 9.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.2 percentage points from the prior year.

Return on Equity

13.8%

YoY+1.0pp

5Y CAGR-7.3pp

10Y CAGR-1.3pp

Quest Diagnostics Inc's ROE was 13.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 1.0 percentage points from the prior year.

Capital Allocation

Share Buybacks

$450.0M

YoY+198.0%

5Y CAGR+6.7%

10Y CAGR+7.2%

Quest Diagnostics Inc spent $450.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 198.0% from the prior year.

Capital Expenditures

$527.0M

YoY+24.0%

5Y CAGR+4.7%

10Y CAGR+7.2%

Quest Diagnostics Inc invested $527.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 24.0% from the prior year.

R&D Spending

Not reported for fiscal year 2025.

DGX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

DGX annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$11.6B	$11.0B+11.8%	$9.9B+6.7%	$9.3B-6.4%	$9.9B-8.4%	$10.8B+14.3%	$9.4B+22.1%	$7.7B+2.6%	$7.5B+1.7%	$7.4B+2.6%	$7.2B-3.7%	$7.5B+0.8%	$7.4B+4.0%	$7.1B-3.2%	$7.4B-0.1%	$7.4B
Cost of Revenue	$7.7B	$7.4B+11.2%	$6.6B+6.9%	$6.2B-3.9%	$6.5B-2.0%	$6.6B+13.4%	$5.8B+15.2%	$5.0B+2.3%	$4.9B+4.4%	$4.7B+2.2%	$4.6B-0.9%	$4.7B+0.4%	$4.6B+7.2%	$4.3B-0.9%	$4.4B0.0%	$4.4B
Gross Profit	$3.8B	$3.7B+13.0%	$3.2B+6.3%	$3.1B-11.1%	$3.4B-18.4%	$4.2B+15.9%	$3.6B+35.1%	$2.7B+3.2%	$2.6B-2.9%	$2.7B-7.5%	$2.9B+2.2%	$2.8B+1.4%	$2.8B-0.8%	$2.8B-6.6%	$3.0B-0.4%	$3.0B
SG&A Expenses	$2.0B	$2.0B+11.1%	$1.8B+7.8%	$1.6B-12.4%	$1.9B+8.5%	$1.7B+11.4%	$1.6B+6.4%	$1.5B+2.3%	$1.4B-1.3%	$1.4B+4.6%	$1.4B-17.8%	$1.7B-2.8%	$1.7B+1.4%	$1.7B-2.3%	$1.7B+0.1%	$1.7B
Operating Income	$1.6B	$1.6B+15.6%	$1.3B+6.7%	$1.3B-11.6%	$1.4B-40.0%	$2.4B+20.8%	$2.0B+60.1%	$1.2B+11.8%	$1.1B-5.5%	$1.2B-8.8%	$1.3B-8.7%	$1.4B+42.3%	$983.0M-33.4%	$1.5B+22.8%	$1.2B+21.7%	$987.0M
Interest Expense	$269.0M	$277.0M+22.6%	$226.0M+38.7%	$163.0M+10.1%	$148.0M-2.6%	$152.0M-8.4%	$166.0M-7.8%	$180.0M+6.5%	$169.0M+10.5%	$153.0M+6.3%	$144.0M-6.5%	$154.0M-7.8%	$167.0M+205.0%	-$159.0M	N/A	$173.3M
Income Tax	$320.0M	$314.0M+15.0%	$273.0M+10.1%	$248.0M-6.1%	$264.0M-55.8%	$597.0M+29.8%	$460.0M+86.2%	$247.0M+35.7%	$182.0M-24.5%	$241.0M-43.8%	$429.0M+15.0%	$373.0M+42.4%	$262.0M-47.6%	$500.0M+24.4%	$402.0M+13.2%	$355.0M
Net Income	$1.1B	$992.0M+13.9%	$871.0M+2.0%	$854.0M-9.7%	$946.0M-52.6%	$2.0B+39.4%	$1.4B+66.8%	$858.0M+16.6%	$736.0M-4.7%	$772.0M+19.7%	$645.0M-9.0%	$709.0M+27.5%	$556.0M-34.5%	$849.0M+52.7%	$556.0M+18.0%	$471.0M
EPS (Diluted)	—	$8.75+13.8%	$7.69+2.7%	$7.49-6.0%	$7.97-48.7%	$15.55+48.5%	$10.47+66.7%	$6.28+18.7%	$5.29-3.8%	$5.50+22.0%	$4.51-7.4%	$4.87+27.8%	$3.81-31.2%	$5.54+60.1%	$3.46+18.5%	$2.92

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$3.0B+5.1%	$2.9B+3.2%	$2.8B-0.4%	$2.8B+2.0%	$2.8B+4.1%	$2.7B+1.2%	$2.6B+5.3%	$2.5B
Cost of Revenue	$2.0B+3.2%	$2.0B+3.0%	$1.9B+1.6%	$1.9B+2.7%	$1.8B+1.6%	$1.8B+1.5%	$1.8B+5.1%	$1.7B
Gross Profit	$1.0B+9.0%	$942.0M+3.5%	$910.0M-4.1%	$949.0M+0.6%	$943.0M+9.3%	$863.0M+0.6%	$858.0M+5.8%	$811.0M
SG&A Expenses	$529.0M+5.0%	$504.0M0.0%	$504.0M+0.6%	$501.0M+3.1%	$486.0M+2.1%	$476.0M+2.1%	$466.0M+4.0%	$448.0M
Operating Income	$459.0M+15.0%	$399.0M+3.4%	$386.0M0.0%	$386.0M-11.9%	$438.0M+26.6%	$346.0M-4.2%	$361.0M+9.4%	$330.0M
Interest Expense	$68.0M+4.6%	$65.0M-3.0%	$67.0M-2.9%	$69.0M0.0%	$69.0M-4.2%	$72.0M0.0%	$72.0M+24.1%	$58.0M
Income Tax	$88.0M+18.9%	$74.0M-8.6%	$81.0M+5.2%	$77.0M-20.6%	$97.0M+64.4%	$59.0M-13.2%	$68.0M+4.6%	$65.0M
Net Income	$320.0M+27.0%	$252.0M+2.9%	$245.0M0.0%	$245.0M-13.1%	$282.0M+28.2%	$220.0M-0.9%	$222.0M-1.8%	$226.0M
EPS (Diluted)	$2.84+26.8%	$2.24	N/A	$2.16-12.6%	$2.47+27.3%	$1.94	N/A	$1.99

Not reported in any period shown, so not listed: R&D Expenses.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

DGX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

DGX annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$16.2B+0.4%	$16.2B+15.2%	$14.0B+9.2%	$12.8B-5.7%	$13.6B-3.0%	$14.0B+9.2%	$12.8B+16.7%	$11.0B+4.8%	$10.5B+4.0%	$10.1B+1.4%	$10.0B+1.1%	$9.9B+10.2%	$8.9B-3.6%	$9.3B-0.3%	$9.3B
Current Assets	$2.4B-0.6%	$2.4B+0.8%	$2.4B+25.0%	$1.9B-30.8%	$2.7B-10.4%	$3.1B+22.8%	$2.5B+79.1%	$1.4B+6.4%	$1.3B-14.7%	$1.5B+2.0%	$1.5B-6.4%	$1.6B+15.9%	$1.4B-11.4%	$1.6B+11.4%	$1.4B
Cash & Equivalents	$420.0M-23.5%	$549.0M-20.0%	$686.0M+117.8%	$315.0M-63.9%	$872.0M-24.7%	$1.2B-2.9%	$1.2B+783.0%	$135.0M-1.5%	$137.0M-61.8%	$359.0M+169.9%	$133.0M-30.7%	$192.0M+2.7%	$187.0M-36.8%	$296.0M+79.4%	$165.0M
Inventory	$189.0M+0.5%	$188.0M-1.1%	$190.0M-1.0%	$192.0M-7.7%	$208.0M-6.7%	$223.0M+81.3%	$123.0M+24.2%	$99.0M+4.2%	$95.0M+15.9%	$82.0M-2.4%	$84.0M-23.6%	$110.0M+20.9%	$91.0M-2.2%	$93.0M+4.3%	$89.1M
Accounts Receivable	$1.4B+8.0%	$1.3B+7.8%	$1.2B+1.3%	$1.2B-16.9%	$1.4B-5.4%	$1.5B+43.0%	$1.1B+5.0%	$1.0B+9.5%	$924.0M-0.2%	$926.0M+2.8%	$901.0M-3.3%	$932.0M+9.4%	$852.0M-1.7%	$867.0M-4.4%	$906.5M
Goodwill	$8.9B+1.0%	$8.9B+14.5%	$7.7B+7.1%	$7.2B+1.8%	$7.1B+3.2%	$6.9B+3.8%	$6.6B+0.9%	$6.6B+3.6%	$6.3B+5.6%	$6.0B+1.6%	$5.9B-2.1%	$6.0B+6.8%	$5.6B+2.0%	$5.5B-4.5%	$5.8B
Total Liabilities	$9.1B-3.4%	$9.4B+21.5%	$7.7B+11.1%	$6.9B-3.1%	$7.2B-1.4%	$7.3B+0.9%	$7.2B+24.5%	$5.8B+3.7%	$5.6B+2.0%	$5.5B+3.7%	$5.3B-5.0%	$5.6B+11.1%	$5.0B-2.4%	$5.1B-8.9%	$5.6B
Current Liabilities	$2.3B+5.0%	$2.2B+19.5%	$1.8B+17.0%	$1.6B-11.5%	$1.8B-1.3%	$1.8B-10.8%	$2.0B+34.0%	$1.5B+40.5%	$1.1B+7.7%	$981.0M-16.4%	$1.2B-31.4%	$1.7B+51.0%	$1.1B+8.0%	$1.0B-32.9%	$1.6B
Long-Term Debt	$5.2B-8.0%	$5.6B+27.3%	$4.4B+10.9%	$4.0B-0.8%	$4.0B-0.1%	$4.0B+1.2%	$4.0B+15.7%	$3.4B-8.5%	$3.7B+0.5%	$3.7B+6.8%	$3.5B+8.3%	$3.2B+3.3%	$3.1B-7.0%	$3.4B-0.5%	$3.4B
Total Equity	$7.2B+5.8%	$6.8B+7.5%	$6.3B+7.0%	$5.9B-8.6%	$6.4B-4.7%	$6.8B+19.8%	$5.6B+8.1%	$5.2B+6.0%	$4.9B+6.3%	$4.6B-1.2%	$4.7B+8.9%	$4.3B+8.9%	$3.9B-5.2%	$4.2B+12.7%	$3.7B
Retained Earnings	$10.0B+6.8%	$9.4B+6.1%	$8.8B+6.5%	$8.3B+8.4%	$7.6B-17.8%	$9.3B+13.8%	$8.2B+7.5%	$7.6B+6.5%	$7.1B+7.9%	$6.6B+6.7%	$6.2B+8.3%	$5.7B+6.8%	$5.4B+14.2%	$4.7B+10.0%	$4.3B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$16.9B+1.6%	$16.7B+2.8%	$16.2B+0.2%	$16.2B+1.4%	$16.0B+1.1%	$15.8B-2.2%	$16.2B+0.4%	$16.1B
Current Assets	$2.8B+10.8%	$2.6B+7.9%	$2.4B-1.2%	$2.4B+9.5%	$2.2B+5.9%	$2.1B-13.3%	$2.4B-8.8%	$2.6B
Cash & Equivalents	$626.0M+59.3%	$393.0M-6.4%	$420.0M-2.8%	$432.0M+35.4%	$319.0M+69.7%	$188.0M-65.8%	$549.0M-28.1%	$764.0M
Inventory	$233.0M+3.6%	$225.0M+19.0%	$189.0M+1.6%	$186.0M-0.5%	$187.0M-1.1%	$189.0M+0.5%	$188.0M+2.2%	$184.0M
Accounts Receivable	$1.7B+5.0%	$1.6B+12.7%	$1.4B-3.3%	$1.5B+2.6%	$1.4B+1.1%	$1.4B+7.7%	$1.3B-5.2%	$1.4B
Goodwill	$9.1B-0.1%	$9.1B+2.0%	$8.9B+0.5%	$8.9B+0.2%	$8.9B+0.4%	$8.8B-0.1%	$8.9B+2.9%	$8.6B
Total Liabilities	$9.4B+1.2%	$9.3B+2.8%	$9.1B+1.3%	$8.9B+2.3%	$8.7B-1.4%	$8.9B-5.4%	$9.4B+1.0%	$9.3B
Current Liabilities	$1.8B-17.9%	$2.2B-4.4%	$2.3B+6.7%	$2.1B+5.4%	$2.0B+40.5%	$1.4B-33.6%	$2.2B+3.7%	$2.1B
Long-Term Debt	$5.6B+9.3%	$5.2B-0.2%	$5.2B-0.1%	$5.2B0.0%	$5.2B-11.8%	$5.9B+4.3%	$5.6B-0.6%	$5.6B
Total Equity	$7.5B+2.0%	$7.4B+2.7%	$7.2B-1.2%	$7.3B+0.4%	$7.2B+4.3%	$6.9B+2.2%	$6.8B-0.5%	$6.8B
Retained Earnings	$10.4B+2.2%	$10.2B+1.6%	$10.0B+1.6%	$9.8B+1.6%	$9.7B+2.0%	$9.5B+1.4%	$9.4B+1.5%	$9.2B

DGX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

DGX annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$1.9B	$1.9B+41.4%	$1.3B+4.9%	$1.3B-26.0%	$1.7B-23.1%	$2.2B+11.4%	$2.0B+61.3%	$1.2B+3.6%	$1.2B+2.1%	$1.2B+5.3%	$1.1B+35.9%	$821.0M-13.0%	$944.0M+44.8%	$652.0M-45.1%	$1.2B+32.6%	$895.0M
Capital Expenditures	$554.0M	$527.0M+24.0%	$425.0M+4.2%	$408.0M+1.0%	$404.0M+0.2%	$403.0M-3.6%	$418.0M+4.5%	$400.0M+4.4%	$383.0M+52.0%	$252.0M-14.0%	$293.0M+11.4%	$263.0M-14.6%	$308.0M+33.3%	$231.0M+26.9%	$182.0M+13.0%	$161.0M
Free Cash Flow	$1.3B	$1.4B+49.5%	$909.0M+5.2%	$864.0M-34.2%	$1.3B-28.2%	$1.8B+15.3%	$1.6B+88.3%	$843.0M+3.2%	$817.0M-11.5%	$923.0M+12.2%	$823.0M+47.5%	$558.0M-12.3%	$636.0M+51.1%	$421.0M-58.1%	$1.0B+36.9%	$734.0M
Investing Cash Flow	-$678.0M	-$631.0M+75.2%	-$2.5B-140.2%	-$1.1B-95.4%	-$543.0M-2685.7%	$21.0M+102.7%	-$772.0M-87.8%	-$411.0M+48.7%	-$801.0M+3.5%	-$830.0M-553.5%	-$127.0M+64.9%	-$362.0M+64.7%	-$1.0B-412.5%	$328.0M+251.2%	-$217.0M+82.5%	-$1.2B
Financing Cash Flow	-$915.0M	-$1.4B-228.0%	$1.1B+577.5%	$160.0M+109.2%	-$1.7B+31.8%	-$2.5B-100.5%	-$1.3B-663.1%	$225.0M+156.1%	-$401.0M+32.3%	-$592.0M+19.8%	-$738.0M-42.5%	-$518.0M-702.3%	$86.0M+107.8%	-$1.1B-34.5%	-$822.0M-1384.4%	$64.0M
Dividends Paid	$363.0M	$353.0M+6.6%	$331.0M+5.4%	$314.0M+3.0%	$305.0M-1.3%	$309.0M+4.0%	$297.0M+3.8%	$286.0M+7.5%	$266.0M+7.7%	$247.0M+10.8%	$223.0M+5.2%	$212.0M+13.4%	$187.0M+1.1%	$185.0M+71.3%	$108.0M+66.2%	$65.0M
Share Buybacks	N/A	$450.0M+198.0%	$151.0M-45.1%	$275.0M-80.5%	$1.4B-36.0%	$2.2B+576.6%	$325.0M-7.9%	$353.0M+9.6%	$322.0M-30.8%	$465.0M-21.2%	$590.0M+163.4%	$224.0M+69.7%	$132.0M-87.3%	$1.0B+418.5%	$200.0M-78.6%	$935.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$597.0M+114.7%	$278.0M-40.2%	$465.0M-17.4%	$563.0M+3.5%	$544.0M+73.2%	$314.0M-32.3%	$464.0M+30.3%	$356.0M
Capital Expenditures	$138.0M+21.1%	$114.0M-27.8%	$158.0M+9.7%	$144.0M+33.3%	$108.0M-7.7%	$117.0M-4.9%	$123.0M+16.0%	$106.0M
Free Cash Flow	$459.0M+179.9%	$164.0M-46.6%	$307.0M-26.7%	$419.0M-3.9%	$436.0M+121.3%	$197.0M-42.2%	$341.0M+36.4%	$250.0M
Investing Cash Flow	-$134.0M+11.8%	-$152.0M+20.4%	-$191.0M+5.0%	-$201.0M-62.1%	-$124.0M-7.8%	-$115.0M+77.1%	-$502.0M+69.3%	-$1.6B
Financing Cash Flow	-$229.0M-50.7%	-$152.0M+47.0%	-$287.0M-16.2%	-$247.0M+15.7%	-$293.0M+47.8%	-$561.0M-230.0%	-$170.0M-109.6%	$1.8B
Dividends Paid	$96.0M+9.1%	$88.0M-2.2%	$90.0M+1.1%	$89.0M-1.1%	$90.0M+7.1%	$84.0M0.0%	$84.0M0.0%	$84.0M
Share Buybacks	N/A	N/A	$300.0M+100.0%	$150.0M	N/A	N/A	$151.0M	N/A

DGX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

DGX annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	33.2%+0.4pp	32.9%-0.1pp	33.0%-1.7pp	34.7%-4.3pp	39.0%+0.5pp	38.5%+3.7pp	34.8%+0.2pp	34.6%-1.7pp	36.3%-3.9pp	40.2%+2.3pp	37.9%+0.2pp	37.6%-1.8pp	39.5%-1.4pp	40.9%-0.1pp	41.0%
Operating Margin	14.1%+0.5pp	13.6%0.0pp	13.6%-0.8pp	14.4%-7.6pp	22.1%+1.2pp	20.9%+5.0pp	15.9%+1.3pp	14.6%-1.1pp	15.7%-2.0pp	17.7%-1.0pp	18.7%+5.4pp	13.2%-7.4pp	20.6%+4.4pp	16.3%+2.9pp	13.4%
Net Margin	9.0%+0.2pp	8.8%-0.4pp	9.2%-0.3pp	9.6%-8.9pp	18.5%+3.3pp	15.2%+4.1pp	11.1%+1.3pp	9.8%-0.7pp	10.4%+1.5pp	8.9%-0.5pp	9.5%+2.0pp	7.5%-4.4pp	11.9%+4.3pp	7.5%+1.2pp	6.4%
Return on Equity	13.8%+1.0pp	12.8%-0.7pp	13.5%-2.5pp	16.1%-14.9pp	31.0%+9.8pp	21.2%+6.0pp	15.2%+1.1pp	14.1%-1.6pp	15.7%+1.8pp	13.9%-1.2pp	15.1%+2.2pp	12.9%-8.6pp	21.5%+8.1pp	13.4%+0.6pp	12.8%
Return on Assets	6.1%+0.7pp	5.4%-0.7pp	6.1%-1.3pp	7.4%-7.3pp	14.7%+4.5pp	10.2%+3.5pp	6.7%0.0pp	6.7%-0.7pp	7.3%+1.0pp	6.4%-0.7pp	7.1%+1.5pp	5.6%-3.9pp	9.5%+3.5pp	6.0%+0.9pp	5.1%
Current Ratio	1.04-0.1x	1.10-0.2x	1.31+0.1x	1.22-0.3x	1.56-0.2x	1.72+0.5x	1.25+0.3x	0.94-0.3x	1.24-0.3x	1.56+0.3x	1.28+0.3x	0.94-0.3x	1.22-0.3x	1.49+0.6x	0.90
Debt-to-Equity	0.72-0.1x	0.83+0.1x	0.700.0x	0.68+0.1x	0.620.0x	0.59-0.1x	0.700.0x	0.66-0.1x	0.760.0x	0.81+0.1x	0.750.0x	0.750.0x	0.790.0x	0.81-0.1x	0.91
FCF Margin	12.3%+3.1pp	9.2%-0.1pp	9.3%-4.0pp	13.3%-3.7pp	17.0%+0.1pp	16.8%+5.9pp	10.9%+0.1pp	10.8%-1.6pp	12.5%+1.1pp	11.4%+4.0pp	7.4%-1.1pp	8.6%+2.7pp	5.9%-7.7pp	13.6%+3.7pp	9.9%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	33.8%+1.2pp	32.5%+0.1pp	32.4%-1.3pp	33.7%-0.5pp	34.2%+1.6pp	32.5%-0.2pp	32.7%+0.1pp	32.6%
Operating Margin	15.1%+1.3pp	13.8%0.0pp	13.8%+0.1pp	13.7%-2.1pp	15.9%+2.8pp	13.1%-0.7pp	13.8%+0.5pp	13.3%
Net Margin	10.5%+1.8pp	8.7%0.0pp	8.7%0.0pp	8.7%-1.5pp	10.2%+1.9pp	8.3%-0.2pp	8.5%-0.6pp	9.1%
Return on Equity	4.3%+0.8pp	3.4%0.0pp	3.4%0.0pp	3.4%-0.5pp	3.9%+0.7pp	3.2%-0.1pp	3.3%0.0pp	3.3%
Return on Assets	1.9%+0.4pp	1.5%0.0pp	1.5%0.0pp	1.5%-0.3pp	1.8%+0.4pp	1.4%0.0pp	1.4%0.0pp	1.4%
Current Ratio	1.59+0.4x	1.18+0.1x	1.04-0.1x	1.130.0x	1.09-0.4x	1.44+0.3x	1.10-0.2x	1.25
Debt-to-Equity	0.750.0x	0.700.0x	0.720.0x	0.710.0x	0.72-0.1x	0.850.0x	0.830.0x	0.83
FCF Margin	15.1%+9.4pp	5.7%-5.3pp	10.9%-3.9pp	14.9%-0.9pp	15.8%+8.4pp	7.4%-5.6pp	13.0%+3.0pp	10.1%

Similar Companies

Labcorp Holdings Inc LH

$26.8B

$40.9B

$46.9B

$14.5B

$28.6B

Where Quest Diagnostics Inc Ranks

Frequently Asked Questions

What is Quest Diagnostics Inc's annual revenue?

Quest Diagnostics Inc (DGX) reported $11.0B in total revenue for fiscal year 2025. This represents a 11.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Quest Diagnostics Inc's revenue growing?

Quest Diagnostics Inc (DGX) revenue grew by 11.8% year-over-year, from $9.9B to $11.0B in fiscal year 2025.

Is Quest Diagnostics Inc profitable?

Yes, Quest Diagnostics Inc (DGX) reported a net income of $992.0M in fiscal year 2025, with a net profit margin of 9.0%.

What is Quest Diagnostics Inc's EBITDA?

Quest Diagnostics Inc (DGX) had EBITDA of $2.1B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Quest Diagnostics Inc have?

As of fiscal year 2025, Quest Diagnostics Inc (DGX) had $420.0M in cash and equivalents against $5.2B in long-term debt.

What is Quest Diagnostics Inc's gross margin?

Quest Diagnostics Inc (DGX) had a gross margin of 33.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Quest Diagnostics Inc's operating margin?

Quest Diagnostics Inc (DGX) had an operating margin of 14.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Quest Diagnostics Inc's net profit margin?

Quest Diagnostics Inc (DGX) had a net profit margin of 9.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Quest Diagnostics Inc's return on equity (ROE)?

Quest Diagnostics Inc (DGX) has a return on equity of 13.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Quest Diagnostics Inc's free cash flow?

Quest Diagnostics Inc (DGX) generated $1.4B in free cash flow during fiscal year 2025. This represents a 49.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Quest Diagnostics Inc's operating cash flow?

Quest Diagnostics Inc (DGX) generated $1.9B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Quest Diagnostics Inc's total assets?

Quest Diagnostics Inc (DGX) had $16.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Quest Diagnostics Inc's capital expenditures?

Quest Diagnostics Inc (DGX) invested $527.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does Quest Diagnostics Inc buy back shares?

Yes, Quest Diagnostics Inc (DGX) spent $450.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Quest Diagnostics Inc have outstanding?

Quest Diagnostics Inc (DGX) had 110M shares outstanding as of fiscal year 2025.

What is Quest Diagnostics Inc's current ratio?

Quest Diagnostics Inc (DGX) had a current ratio of 1.04 as of fiscal year 2025, which is considered adequate.

What is Quest Diagnostics Inc's debt-to-equity ratio?

Quest Diagnostics Inc (DGX) had a debt-to-equity ratio of 0.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Quest Diagnostics Inc's return on assets (ROA)?

Quest Diagnostics Inc (DGX) had a return on assets of 6.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Quest Diagnostics Inc's Altman Z-Score?

Quest Diagnostics Inc (DGX) has an Altman Z-Score of 3.63, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Quest Diagnostics Inc's Piotroski F-Score?

Quest Diagnostics Inc (DGX) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Quest Diagnostics Inc's earnings high quality?

Quest Diagnostics Inc (DGX) has an earnings quality ratio of 1.90x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Quest Diagnostics Inc cover its interest payments?

Quest Diagnostics Inc (DGX) has an interest coverage ratio of 5.62x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Quest Diagnostics Inc?

Quest Diagnostics Inc (DGX) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.